An Open-Label, Randomized Phase 2 Study of the Impact of Food on Tolerability When Receiving Abemaciclib for Patients With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Sep 2019
Price : $35 *
At a glance
- Drugs Abemaciclib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 02 Aug 2019 Planned primary completion date changed from 20 Jul 2019 to 25 Jul 2019.
- 21 May 2019 Status changed from recruiting to active, no longer recruiting.
- 02 Mar 2019 Planned primary completion date changed from 20 Feb 2020 to 20 Jul 2019.